1. Scrip

Immunomedics’ ASCENT Confirms Trodelvy’s Efficacy In Triple-Negative Breast Cancer

 
• By Mandy Jackson

After accelerated approval in the US in April based on Phase II response rates, the company will seek full approval later this year based on a tripling of progression-free survival in a Phase III trial.

Healthcare success and patients to succeed in medical care or successful doctor concept as a stethoscope solving a maze to hit the target and succeed as a 3D illustration.
Trodelvy could find its way to more TNBC patients based on Phase III data • Source: Shutterstock

Immunomedics, Inc. reported top-line results from the Phase III ASCENT clinical trial on 6 July for Trodelvy in which progression-free survival (PFS) was three times as long for patients with previously treated metastatic triple-negative breast cancer (TNBC) who were treated with the antibody-drug conjugate (ADC) targeting Trop-2 compared with patients who received chemotherapy. More detailed results could improve uptake and reimbursement for the recently launched product.

Trodelvy (sacituzumab govitecan-hziy) received accelerated US Food and Drug Administration approval in April for the treatment of metastatic TNBC patients who have received at least two prior lines of therapy based on the objective response rate (ORR) in a Phase II study

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

More from R&D